Neurocentria, Inc. Company Profile, Contacts & Intelligence

Biotechnology ResearchWalnut Creek, California, United States14 employeesFounded 2005
3 contacts with email or phone data3 with email data1 with phone data
Employees
14
Company source estimate
Reachable Contacts
3
Visible contacts with email or phone data
Contacts With Email
3
3 of 4 visible contacts

Neurocentria, Inc. Overview

Neurocentria is a late-stage biotechnology company dedicated to discovering and developing novel treatments for neurodegenerative and neuropsychiatric disorders, including ADHD, depression and Alzheimer’s disease. Since 2005, our team has been innovating breakthrough therapies to address the pathophysiology of these disorders, prevent their progression or even reverse their course, reduce symptoms and improve patients’ performance and quality of life. Currently available treatments for these disorders are acting on classical targets identified decades ago, especially for ADHD and depression, with no new approaches introduced during this time. And, too often, patients endure just as much from the side effects of their medications. Our novel therapy, NRCT-101SR, is a new class of treatment for neurological disorders, developed to act on new molecular targets. In preclinical studies, NRCT-101, the API of NRCT-101SR, increased synapse density and plasticity, improving synaptic function. Importantly, NRCT-101 enhanced cognitive function and improved emotional regulation in young animals, and prevented synaptic loss and alleviated cognitive impairment in aged animals. Similar effects of NRCT-101 were seen in models of neuroinflammation. In early-stage human clinical trials, NRCT-101 was shown to: ➫ Improve mood status in 3-7 days versus the several weeks it takes for most medications ➫ Address ADHD symptoms without imposing side effects ➫ Improve cognition for adults with late-life depression, anxiety, ADHD and Alzheimer’s & Alzheimer’s-like symptoms ➫ Produce no negative side effects The FDA recently approved our drug candidate for a pivotal Phase IIb/III human trial for adults with ADHD, a Phase IIb human trial in Alzheimer’s, and we are working on a phase IIb/III human trial in adults with major depressive disorder. We are fully committed to developing novel brain health therapies that are safe, improve people’s conditions and promote healthy communities.

Headquarters
Walnut Creek, California, United States
Industry
Biotechnology Research
Founded
2005
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Phone Number
Available in AeroLeads
Company Email
Available in AeroLeads

Neurocentria, Inc. Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

3 contacts with contact data
3 with email data and 1 with phone data in the visible sample.

Neurocentria, Inc. People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Neurocentria, Inc. Workforce Composition

Seniority breakdown across 4 visible profiles.

Individual contributor
3
Director
1

Compare Similar Companies to Neurocentria, Inc.

Explore companies in related markets and compare their industry and employee estimates.

Company Industry / match Employee estimate Page
Neurocrine Biosciences Biotechnology Research 1.98K View company
BridgeBio Biotechnology Research 778 View company
Denali Therapeutics Biotechnology Research 549 View company
Eikon Therapeutics Biotechnology Research 394 View company
Neumora Biotechnology Research 122 View company
Neurona Therapeutics Biotechnology Research 97 View company
Alto Neuroscience Biotechnology 77 View company
Sunwise Clinical Research, LLC Research Services 15 View company
OrphAI Therapeutics Biotechnology Research 12 View company
Reservoir Neuroscience Biotechnology Research 4 View company